Aytu BioPharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Aytu BioPharma is de winst gegroeid met een gemiddeld jaarlijks percentage van 40.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 10.7%. De inkomsten zijn gedaald met een gemiddelde van 5.8% per jaar.
Belangrijke informatie
40.87%
Groei van de winst
67.25%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 5.95% |
| Inkomstengroei | -5.79% |
| Rendement op eigen vermogen | -97.08% |
| Nettomarge | -60.28% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Jun 26
AYTU: Higher Margins And Lower P/E Will Support Future Upside
Aytu BioPharma’s analyst price target has shifted from $12.50 to $14.50, with analysts pointing to updated assumptions for higher revenue growth, stronger profit margins, and a lower future P/E multiple as key drivers of the new outlook. What's in the News No recent company specific news items were identified for Aytu BioPharma from the provided sources.Analyse-artikel • Dec 20
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...Analyse-artikel • Nov 17
Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...Analyse-artikel • Oct 30
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise
Those holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...Analyse-artikel • Jul 29
Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...Analyse-artikel • May 14
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...Analyse-artikel • May 04
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Analyse-artikel • Jan 18
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Analyse-artikel • Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...Analyse-artikel • Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyse-artikel • Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...Analyse-artikel • Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...Analyse-artikel • Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...Analyse-artikel • Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...Seeking Alpha • Oct 13
Aytu stock falls amid suspending clinical programs to save costs
Aytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.Seeking Alpha • Sep 27
Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.Seeking Alpha • Sep 14
Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.Seeking Alpha • Aug 16
Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16Seeking Alpha • Aug 09
Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.Analyse-artikel • May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...Analyse-artikel • Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Opbrengsten en kosten
Opbrengsten en kosten
Hoe Aytu BioPharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 57 | -34 | 41 | 0 |
| 31 Dec 25 | 63 | -25 | 39 | 0 |
| 30 Sep 25 | 64 | -13 | 38 | 1 |
| 30 Jun 25 | 66 | -14 | 38 | 1 |
| 31 Mar 25 | 66 | 2 | 39 | 2 |
| 31 Dec 24 | 61 | -4 | 40 | 3 |
| 30 Sep 24 | 64 | -4 | 40 | 3 |
| 30 Jun 24 | 65 | -13 | 42 | 3 |
| 31 Mar 24 | 81 | -12 | 47 | 2 |
| 31 Dec 23 | 90 | -17 | 56 | 2 |
| 30 Sep 23 | 98 | -24 | 65 | 4 |
| 30 Jun 23 | 74 | -8 | 50 | 4 |
| 31 Mar 23 | 104 | -31 | 73 | 7 |
| 31 Dec 22 | 106 | -77 | 71 | 9 |
| 30 Sep 22 | 102 | -82 | 70 | 12 |
| 30 Jun 22 | 97 | -109 | 70 | 13 |
| 31 Mar 22 | 93 | -112 | 73 | 14 |
| 31 Dec 21 | 82 | -84 | 68 | 11 |
| 30 Sep 21 | 74 | -82 | 62 | 7 |
| 30 Jun 21 | 66 | -58 | 56 | 6 |
| 31 Mar 21 | 57 | -42 | 47 | 2 |
| 31 Dec 20 | 52 | -22 | 42 | 2 |
| 30 Sep 20 | 40 | -13 | 37 | 2 |
| 30 Jun 20 | 28 | -14 | 31 | 2 |
| 31 Mar 20 | 14 | -25 | 24 | 0 |
| 31 Dec 19 | 9 | -24 | 22 | 0 |
| 30 Sep 19 | 7 | -29 | 21 | 1 |
| 30 Jun 19 | 7 | -27 | 19 | 1 |
| 31 Mar 19 | 7 | -12 | 18 | 1 |
| 31 Dec 18 | 5 | -10 | 18 | 1 |
| 30 Sep 18 | 4 | -9 | 17 | 0 |
| 30 Jun 18 | 4 | -10 | 18 | 0 |
| 31 Mar 18 | 4 | -17 | 17 | 0 |
| 31 Dec 17 | 4 | -20 | 17 | 1 |
| 30 Sep 17 | 4 | -21 | 16 | 1 |
| 30 Jun 17 | 3 | -23 | 17 | 1 |
| 31 Mar 17 | 3 | -31 | 17 | 4 |
| 31 Dec 16 | 3 | -33 | 15 | 5 |
| 30 Sep 16 | 3 | -32 | 13 | 6 |
| 30 Jun 16 | 3 | -28 | 9 | 6 |
| 31 Mar 16 | 2 | -15 | 7 | 4 |
| 31 Dec 15 | 1 | -10 | 6 | 4 |
| 30 Sep 15 | 1 | -8 | 5 | 3 |
Kwaliteitswinsten: AYTU is momenteel verliesgevend.
Groeiende winstmarge: AYTU is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AYTU is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 40.9% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van AYTU over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: AYTU is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( -4.8% ).
Rendement op eigen vermogen
Hoge ROE: AYTU heeft een negatief Return on Equity ( -97.08% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/13 13:36 |
| Aandelenkoers aan het einde van de dag | 2026/07/13 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Aytu BioPharma, Inc. wordt gevolgd door 5 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Thomas Flaten | Lake Street Capital Markets, LLC |